ClinicalTrials.gg
CompletedNCT00576758Updated Aug 19, 2014Results posted

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

A Phase 2 interventional study of obinutuzumab (RO5072759) and rituximab in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 71 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-19.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, none of them phase 3. obinutuzumab · Lymphoma, Non-Hodgkin.

Enrollment
5th of 15
175 · median 41
Started
2008
the only one that year
Phase 2
8 of 15
2 open now
Registered
1st of 15
by date
Lead sponsor
5 of 15
Hoffmann-La Roche

Among the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, this one is the 5th largest by enrollment, is the only one that started in 2008, is one of 8 in phase 2, and was the 1st registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About obinutuzumab

obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This study will investigate the efficacy of weekly intravenous obinutuzumab [GA101 (RO5072759)] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma. Patients will be randomized to receive either GA101 or rituximab, given as four weekly infusions. At the conclusion of the initial trial patients may be eligible to continue therapy up to 24 months. The anticipated time on study treatment is 3- 24 months, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age
  • CD20+ indolent B-cell non-Hodgkin's lymphoma
  • documented history of response of >/= 6 months duration from last rituximab-containing regimen
  • clinical indication for treatment as determined by the investigator
  • (ECOG) performance status 0-2

Exclusion criteria

Exclusion Criteria:

  • prior use of any monoclonal antibody within 6 months of study start
  • prior use of any anti-cancer vaccine
  • prior use of rituximab within 8 weeks of study entry
  • radioimmunotherapy within 3 months prior to study entry
  • Central Nervous System (CNS) lymphoma or evidence of transformation to high-grade or diffuse large B-cell lymphoma
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Obinutuzumab

    Participants received 1000 mg obinutuzumab intravenous (IV) infusion once a week on Days 1, 8, 15, and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression, were eligible to receive a 1000 mg IV infusion every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.

    Drug: obinutuzumab (RO5072759)

  • Active comparator
    Rituximab

    Participants received 375 mg/m\^2 rituximab IV infusion once a week on Days 1, 8, 15 and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression were eligible to receive a 375 mg/m\^2 rituximab IV infusion once every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.

    Drug: rituximab

Interventions

  • 1000 mg obinutuzumab intravenous (IV) infusion once a week for 4 weeks.

    Also known as: RO5072759, GA101, GAZYVA®

  • 375 mg/m\^2 rituximab IV infusion once a week for 4 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Response At the End of Induction Period

    Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigator at end of induction treatment. Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. CRu was CR plus one or more of the following: A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of the greatest diameter (tumors)(SPD) and/or indeterminate bone marrow. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.

    Time frame: Randomization to clinical cutoff: 01 September 2011 (Up to 70 days)

Secondary outcomes

  1. Percentage of Participants With Complete Response at the End of the Induction Period

    Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR is defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. All lymph nodes and nodal masses must have regressed to normal size. The spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and must not be palpable on physical examination. Any macroscopic nodules in any organs detectable on imaging techniques should no longer be present. Other organs considered to be enlarged before therapy due to involvement by lymphoma, such as liver and kidneys, must have decreased in size. If the bone marrow was involved by lymphoma before treatment, the infiltrate must be cleared on repeat bone marrow aspirate and biopsy of the same site.

    Time frame: Randomization to clinical cutoff : 01 September 2011 (Up to 70 days)

  2. Percentage of Participants With Partial Response (PR) at the End of the Induction Period

    Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.

    Time frame: Randomization to clinical cutoff : 01 September 2011 (Up to 70 days)

  3. Percentage of Participants With Best Overall Response Achieved at Any Time During the Study Treatment

    Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigators during study treatment (induction or extended treatment phase). Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. CRu was CR plus one or more of the following: A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of the greatest diameter (tumors)(SPD) and/or indeterminate bone marrow. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.

    Time frame: Randomization to clinical cutoff : 01 September 2011 (Up to 70 days)

  4. Number of Participants With Improved Overall Response During the Extended Treatment Period

    Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigators at end of induction treatment. Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson.

    Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)

  5. Percentage of Participants With Best Overall Response Achieved at Any Time During the Study Treatment

    Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigators during study treatment (induction or extended treatment phase). Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. CRu was CR plus one or more of the following: A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of the greatest diameter (tumors)(SPD) and/or indeterminate bone marrow. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.

    Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)

  6. Progression-Free Survival (PFS)

    PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by the Investigator. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.

    Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)

  7. Percentage of Participants With Progression-Free Survival (PFS) Events

    The percentage of participants with progression, relapse, or death events from any cause as assessed by the Investigator. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.

    Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)

  8. Event Free Survival

    Event-free survival (EFS) was defined as the time between date of randomization and the date of disease progression/relapse, death, or start of a new anti-leukemic therapy. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.

    Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)

  9. Percentage of Participants With Event Free Survival (EFS) Events

    Percentage of participants with Event Free Events: disease progression/relapse, death, or start of a new anti-leukemic therapy. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.

    Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)

  10. Duration of Response

    Duration of Response was defined as the date the response, either Complete Response (CR) or Partial Response (PR), was first recorded until the date of Disease Progression or death due to any cause. Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease. Disease Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy.

    Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)

  11. Obinutuzumab Serum PK Parameter: Terminal Half-Life (t1/2)

    Blood was collected for Pharmacokinetic (PK) Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Terminal Half-Life was calculated in days.

    Time frame: Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)

  12. Obinutuzumab Serum PK Parameter: Maximum Serum Concentration (Cmax)

    Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycles 1, 2, 3 and 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Cmax was calculated in micrograms/milliliter (μg/mL).

    Time frame: Day 1 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours post-infusion), Days 8 and 15 (pre-infusion, at end of infusion), Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)

  13. Obinutuzumab Serum PK Parameter: Area Under the Concentration Curve (AUClast)

    Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). AUClast was calculated in days\* micrograms/milliliter (μg/mL)

    Time frame: Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)

  14. Obinutuzumab Serum PK Parameter: Clearance at Steady-State (CLss)

    Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). CLsst was calculated in milliliter/day (mL/day)

    Time frame: Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)

  15. Obinutuzumab Serum PK Parameter: Volume of Distribution at Steady-State (Vss)

    Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Vss was calculated in liters (L).

    Time frame: Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)

  16. Obinutuzumab Serum PK Parameter: Area Under the Concentration Curve Between Dosing Interval (AUCtau)

    Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). AUCtau was calculated in days\* micrograms/milliliter (μg/mL)

    Time frame: Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)

  17. Obinutuzumab Trough Serum Concentration (Ctrough)

    Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycles 2, 3 and 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Ctrough was calculated in micrograms/milliliter (μg/mL).

    Time frame: Days 8 and 15 (pre-infusion, at end of infusion), Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)

  18. Number of Participants With Peripheral Blood B-Cell Depletion

    Blood was collected and sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry at the end of the induction period. B-cell depletion was defined as a CD19 result 5 % of the Baseline value after at least one dose of study drug was administered.

    Time frame: Day 22

  19. Number of Participants With Peripheral Blood B-Cell Recovery

    Blood was sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry. B-cell recovery was defined as the time point when the CD-19 values return to ≥ 50% of baseline levels. The number of participants with B-cell recovery from End of Induction (treatment) Phase to 6 months of Follow-up is reported in two categories: Recovery with Progressive Disease (PD) or Recovery without PD. PD required one of the following: 50 % increase in the absolute number of circulating lymphocytes, Appearance of new palpable lymph nodes, 50 % increase in the longest diameter of any previous site of lymphadenopathy, 50 % increase in the enlargement of the liver and/or spleen or Transformation to a more aggressive histology.

    Time frame: End of last dose + 6 Months Follow-Up

  20. Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

    An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory result), symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution. A SAE was any AE that was one of the following: fatal, life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product or considered a significant medical event by the investigator. Additional information about AEs can be found in the Adverse Event Section.

    Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months) [Includes all AEs reported 28 days after last dose and all Related SAEs regardless of time of last dose.]

  21. Number of Participants With Infusion Related Reactions

    Infusion Related Reactions were AEs that occurred during the infusion or within 24 hours of the infusion.

    Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)

  22. Number of Participants With Human Anti-Chimeric Antibodies (HACA)

    Blood was collected on Day 1 and was sent to a central laboratory for analysis of human anti-chimeric antibodies (anti-rituximab antibodies) using a validated enzyme-linked immunosorbent assay (ELISA). HACA samples were not collected for participants randomized to the rituximab arm.

    Time frame: Day 1

  23. Number of Participants With Human Anti-Human Antibodies (HAHA)

    Blood was collected on Day 1 pre-infusion, during the safety follow-up for those patients who did not enter the Extension period and 6 months after the last infusion of the Extension Period if applicable. Blood was sent to a central laboratory and was tested for anti-obinutuzumab antibodies using a validated enzyme-linked immunosorbent assay (ELISA). HAHA samples were not collected for participants randomized to the rituximab arm.

    Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)

07

Results

Posted Mar 31, 2014

Participant flow

Induction Treatment Period
Participant flow — Induction Treatment Period
MilestoneRituximabObinutuzumab
Started8788
Received treatment8687
Completed7983
Not completed85
Withdrew: Adverse event or intercurrent illness33
Withdrew: Insufficient therapeutic response20
Withdrew: Violation of selection criteria at entry11
Withdrew: Death10
Withdrew: Refused treatment/ did not cooperate01
Withdrew: Withdrew consent10
Extension Treatment Period
Participant flow — Extension Treatment Period
MilestoneRituximabObinutuzumab
Started7273
Completed3030
Not completed4243
Withdrew: Adverse event or intercurrent illness67
Withdrew: Death11
Withdrew: Refused treatment/did not cooperate21
Withdrew: Insufficient therapeutic response3033
Withdrew: Administrative/other31
Follow-up Period
Participant flow — Follow-up Period
MilestoneRituximabObinutuzumab
Started5551
Completed2834
Not completed2717
Withdrew: Administrative/other68
Withdrew: Death33
Withdrew: Insufficient therapeutic response165
Withdrew: Withdrew consent21

Outcome measures

PrimaryPercentage of Participants With Overall Response At the End of Induction Period

Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigator at end of induction treatment. Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. CRu was CR plus one or more of the following: A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of the greatest diameter (tumors)(SPD) and/or indeterminate bone marrow. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.

Time frame:
Randomization to clinical cutoff: 01 September 2011 (Up to 70 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall Response At the End of Induction Period
Percentage of participantsRituximabObinutuzumab
Percentage of Participants With Overall Response At the End of Induction Period33.344.6
Statistical analysis
  • Rituximab vs Obinutuzumab · Chi-squared · p = 0.1587 · Mean difference (final values): 11.26 · 60% CI 3.9 to 18.7
SecondaryPercentage of Participants With Complete Response at the End of the Induction Period

Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR is defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. All lymph nodes and nodal masses must have regressed to normal size. The spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and must not be palpable on physical examination. Any macroscopic nodules in any organs detectable on imaging techniques should no longer be present. Other organs considered to be enlarged before therapy due to involvement by lymphoma, such as liver and kidneys, must have decreased in size. If the bone marrow was involved by lymphoma before treatment, the infiltrate must be cleared on repeat bone marrow aspirate and biopsy of the same site.

Time frame:
Randomization to clinical cutoff : 01 September 2011 (Up to 70 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Response at the End of the Induction Period
Percentage of participantsRituximabObinutuzumab
Percentage of Participants With Complete Response at the End of the Induction Period5.3 (1.5 to 13.1)12.2 (5.7 to 21.8)
Statistical analysis
  • Rituximab vs Obinutuzumab · Mean difference (final values): 6.83 · 95% CI -2.9 to 16.6
SecondaryPercentage of Participants With Partial Response (PR) at the End of the Induction Period

Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.

Time frame:
Randomization to clinical cutoff : 01 September 2011 (Up to 70 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Partial Response (PR) at the End of the Induction Period
Percentage of participantsRituximabObinutuzumab
Percentage of Participants With Partial Response (PR) at the End of the Induction Period28.0 (18.2 to 39.6)32.4 (22.0 to 44.3)
SecondaryPercentage of Participants With Best Overall Response Achieved at Any Time During the Study Treatment

Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigators during study treatment (induction or extended treatment phase). Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. CRu was CR plus one or more of the following: A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of the greatest diameter (tumors)(SPD) and/or indeterminate bone marrow. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.

Time frame:
Randomization to clinical cutoff : 01 September 2011 (Up to 70 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Overall Response Achieved at Any Time During the Study Treatment
Percentage of participantsRituximabObinutuzumab
Complete Response18.7 (10.6 to 29.3)35.1 (24.4 to 47.1)
Partial Response45.3 (33.8 to 57.3)31.1 (20.8 to 42.9)
Stable Disease26.7 (17.1 to 38.1)21.6 (12.9 to 32.7)
Progressive Disease5.3 (1.5 to 13.1)8.1 (3.0 to 16.8)
SecondaryNumber of Participants With Improved Overall Response During the Extended Treatment Period

Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigators at end of induction treatment. Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson.

Time frame:
Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Reported as:
Number · Participants
Number of Participants With Improved Overall Response During the Extended Treatment Period
ParticipantsRituximabObinutuzumab
Number of Participants With Improved Overall Response During the Extended Treatment Period3132
SecondaryPercentage of Participants With Best Overall Response Achieved at Any Time During the Study Treatment

Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigators during study treatment (induction or extended treatment phase). Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. CRu was CR plus one or more of the following: A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of the greatest diameter (tumors)(SPD) and/or indeterminate bone marrow. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.

Time frame:
Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Overall Response Achieved at Any Time During the Study Treatment
Percentage of participantsRituximabObinutuzumab
Complete Response22.7 (13.8 to 33.8)41.9 (30.5 to 53.9)
Partial Response41.3 (30.1 to 53.3)24.3 (15.1 to 35.7)
Stable Disease26.7 (17.1 to 38.1)21.6 (12.9 to 32.7)
Progressive Disease5.3 (1.5 to 13.1)8.1 (3.0 to 16.8)
No Response Assessment4.0 (NA to NA)4.1 (NA to NA)
Statistical analysis
  • Rituximab vs Obinutuzumab · Mean difference (final values): 2.22 · 95% CI -13.9 to 18.3
SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by the Investigator. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.

Time frame:
Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Reported as:
Median · Days
Progression-Free Survival (PFS)
DaysRituximabObinutuzumab
Progression-Free Survival (PFS)772 (425 to 867)536 (394 to NA)
Statistical analysis
  • Rituximab vs Obinutuzumab · Hazard ratio (hr): 0.93 · 95% CI 0.62 to 1.44
SecondaryPercentage of Participants With Progression-Free Survival (PFS) Events

The percentage of participants with progression, relapse, or death events from any cause as assessed by the Investigator. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.

Time frame:
Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Progression-Free Survival (PFS) Events
Percentage of participantsRituximabObinutuzumab
Percentage of Participants With Progression-Free Survival (PFS) Events57.751.4
SecondaryEvent Free Survival

Event-free survival (EFS) was defined as the time between date of randomization and the date of disease progression/relapse, death, or start of a new anti-leukemic therapy. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.

Time frame:
Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Reported as:
Median · Days
Event Free Survival
DaysRituximabObinutuzumab
Event Free Survival472.0 (362 to 772)472.0 (318 to 605)
Statistical analysis
  • Rituximab vs Obinutuzumab · Hazard ratio (hr): 1.00 · 95% CI 0.67 to 1.50
SecondaryPercentage of Participants With Event Free Survival (EFS) Events

Percentage of participants with Event Free Events: disease progression/relapse, death, or start of a new anti-leukemic therapy. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.

Time frame:
Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Event Free Survival (EFS) Events
Percentage of participantsRituximabObinutuzumab
Percentage of Participants With Event Free Survival (EFS) Events64.063.5
SecondaryDuration of Response

Duration of Response was defined as the date the response, either Complete Response (CR) or Partial Response (PR), was first recorded until the date of Disease Progression or death due to any cause. Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease. Disease Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy.

Time frame:
Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Reported as:
Median · Months
Duration of Response
MonthsRituximabObinutuzumab
Duration of Response809 (412 to NA)NA (672 to NA)
SecondaryObinutuzumab Serum PK Parameter: Terminal Half-Life (t1/2)

Blood was collected for Pharmacokinetic (PK) Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Terminal Half-Life was calculated in days.

Time frame:
Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Reported as:
Mean · days
Obinutuzumab Serum PK Parameter: Terminal Half-Life (t1/2)
daysObinutuzumab
Obinutuzumab Serum PK Parameter: Terminal Half-Life (t1/2)41.0 ± 28.6
SecondaryObinutuzumab Serum PK Parameter: Maximum Serum Concentration (Cmax)

Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycles 1, 2, 3 and 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Cmax was calculated in micrograms/milliliter (μg/mL).

Time frame:
Day 1 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours post-infusion), Days 8 and 15 (pre-infusion, at end of infusion), Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Reported as:
Mean · μg/mL
Obinutuzumab Serum PK Parameter: Maximum Serum Concentration (Cmax)
μg/mLObinutuzumab
Cycle 1 (n=74)292 ± 87.4
Cycle 2 (n=78)448 ± 129
Cycle 3 (n=77)561 ± 158
Cycle 4 (n=77)692 ± 213
SecondaryObinutuzumab Serum PK Parameter: Area Under the Concentration Curve (AUClast)

Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). AUClast was calculated in days\* micrograms/milliliter (μg/mL)

Time frame:
Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Reported as:
Mean · day*μg/mL
Obinutuzumab Serum PK Parameter: Area Under the Concentration Curve (AUClast)
day*μg/mLObinutuzumab
Obinutuzumab Serum PK Parameter: Area Under the Concentration Curve (AUClast)23400 ± 10300
SecondaryObinutuzumab Serum PK Parameter: Clearance at Steady-State (CLss)

Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). CLsst was calculated in milliliter/day (mL/day)

Time frame:
Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Reported as:
Mean · mL/day
Obinutuzumab Serum PK Parameter: Clearance at Steady-State (CLss)
mL/dayObinutuzumab
Obinutuzumab Serum PK Parameter: Clearance at Steady-State (CLss)308 ± 470
SecondaryObinutuzumab Serum PK Parameter: Volume of Distribution at Steady-State (Vss)

Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Vss was calculated in liters (L).

Time frame:
Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Reported as:
Mean · Liter
Obinutuzumab Serum PK Parameter: Volume of Distribution at Steady-State (Vss)
LiterObinutuzumab
Obinutuzumab Serum PK Parameter: Volume of Distribution at Steady-State (Vss)14.6 ± 9.8
SecondaryObinutuzumab Serum PK Parameter: Area Under the Concentration Curve Between Dosing Interval (AUCtau)

Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). AUCtau was calculated in days\* micrograms/milliliter (μg/mL)

Time frame:
Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Reported as:
Mean · day*μg/mL
Obinutuzumab Serum PK Parameter: Area Under the Concentration Curve Between Dosing Interval (AUCtau)
day*μg/mLObinutuzumab
Obinutuzumab Serum PK Parameter: Area Under the Concentration Curve Between Dosing Interval (AUCtau)4370 ± 1340
SecondaryObinutuzumab Trough Serum Concentration (Ctrough)

Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycles 2, 3 and 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Ctrough was calculated in micrograms/milliliter (μg/mL).

Time frame:
Days 8 and 15 (pre-infusion, at end of infusion), Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Reported as:
Mean · μg/mL
Obinutuzumab Trough Serum Concentration (Ctrough)
μg/mLObinutuzumab
Cycle 2 (n=78)154 ± 62.7
Cycle 3 (n=77)301 ± 119
Cycle 4 (n=75)418 ± 147
SecondaryNumber of Participants With Peripheral Blood B-Cell Depletion

Blood was collected and sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry at the end of the induction period. B-cell depletion was defined as a CD19 result 5 % of the Baseline value after at least one dose of study drug was administered.

Time frame:
Day 22
Reported as:
Number · Participants
Number of Participants With Peripheral Blood B-Cell Depletion
ParticipantsRituximabObinutuzumab
Number of Participants With Peripheral Blood B-Cell Depletion8082
SecondaryNumber of Participants With Peripheral Blood B-Cell Recovery

Blood was sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry. B-cell recovery was defined as the time point when the CD-19 values return to ≥ 50% of baseline levels. The number of participants with B-cell recovery from End of Induction (treatment) Phase to 6 months of Follow-up is reported in two categories: Recovery with Progressive Disease (PD) or Recovery without PD. PD required one of the following: 50 % increase in the absolute number of circulating lymphocytes, Appearance of new palpable lymph nodes, 50 % increase in the longest diameter of any previous site of lymphadenopathy, 50 % increase in the enlargement of the liver and/or spleen or Transformation to a more aggressive histology.

Time frame:
End of last dose + 6 Months Follow-Up
Reported as:
Number · Participants
Number of Participants With Peripheral Blood B-Cell Recovery
ParticipantsRituximabObinutuzumab
Recovery with PD02
Recovery without PD10
SecondaryNumber of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory result), symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution. A SAE was any AE that was one of the following: fatal, life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product or considered a significant medical event by the investigator. Additional information about AEs can be found in the Adverse Event Section.

Time frame:
Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months) [Includes all AEs reported 28 days after last dose and all Related SAEs regardless of time of last dose.]
Reported as:
Number · Participants
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
ParticipantsRituximabObinutuzumab
AE7483
SAE1721
SecondaryNumber of Participants With Infusion Related Reactions

Infusion Related Reactions were AEs that occurred during the infusion or within 24 hours of the infusion.

Time frame:
Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Reported as:
Number · Participants
Number of Participants With Infusion Related Reactions
ParticipantsRituximabObinutuzumab
Number of Participants With Infusion Related Reactions4470
SecondaryNumber of Participants With Human Anti-Chimeric Antibodies (HACA)

Blood was collected on Day 1 and was sent to a central laboratory for analysis of human anti-chimeric antibodies (anti-rituximab antibodies) using a validated enzyme-linked immunosorbent assay (ELISA). HACA samples were not collected for participants randomized to the rituximab arm.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants With Human Anti-Chimeric Antibodies (HACA)
ParticipantsObinutuzumab
Number of Participants With Human Anti-Chimeric Antibodies (HACA)1
SecondaryNumber of Participants With Human Anti-Human Antibodies (HAHA)

Blood was collected on Day 1 pre-infusion, during the safety follow-up for those patients who did not enter the Extension period and 6 months after the last infusion of the Extension Period if applicable. Blood was sent to a central laboratory and was tested for anti-obinutuzumab antibodies using a validated enzyme-linked immunosorbent assay (ELISA). HAHA samples were not collected for participants randomized to the rituximab arm.

Time frame:
Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Reported as:
Number · Participants
Number of Participants With Human Anti-Human Antibodies (HAHA)
ParticipantsObinutuzumab
Number of Participants With Human Anti-Human Antibodies (HAHA)0

Adverse events

Collected over First dose of study drug to 28 days past last dose of study drug (Up to 27 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab—13/86 (15.1%)70/86 (81.4%)
Obinutuzumab—13/87 (14.9%)79/87 (90.8%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventRituximabObinutuzumab
Febrile neutropeniaBlood and lymphatic system disorders2/862/87
PneumoniaInfections and infestations2/862/87
Infusion related reactionInjury, poisoning and procedural complications1/862/87
NeutropeniaBlood and lymphatic system disorders1/860/87
CellulitisInfections and infestations1/860/87
Fibula fractureInjury, poisoning and procedural complications1/860/87
DyspnoeaRespiratory, thoracic and mediastinal disorders1/860/87
Cardio-respiratory arrestCardiac disorders1/860/87
Hepatitis cholestaticHepatobiliary disorders1/860/87
Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/860/87
Most frequent other events
Showing 10 of 29
Most frequent other events
EventRituximabObinutuzumab
Infusion related reactionsInjury, poisoning and procedural complications43/8662/87
FatigueGeneral disorders17/8623/87
CoughRespiratory, thoracic and mediastinal disorders8/8620/87
PyrexiaGeneral disorders9/865/87
Upper respiratory tract infectionInfections and infestations9/869/87
ArthralgiaMusculoskeletal and connective tissue disorders8/864/87
NauseaGastrointestinal disorders7/868/87
Decreased appetiteMetabolism and nutrition disorders3/868/87
HeadacheNervous system disorders7/868/87
DiarrhoeaGastrointestinal disorders7/867/87

Baseline characteristics

Age, Customized
Age, Customized(participants)RituximabObinutuzumabTotal
<65 years494796
65-70 years222244
>70 years161935
Sex: Female, Male
Sex: Female, Male(Participants)RituximabObinutuzumabTotal
Female434285
Male444690
08

Study locations

71 sites
  • Los angeles, California 90024, United States
  • Denver, Colorado 80220, United States
  • Gainesville, Florida 32610, United States
  • Tampa, Florida 33612, United States
  • Augusta, Georgia 30912, United States
  • Cumberland, Maryland 21502, United States
  • Hackensack, New Jersey 07601, United States
  • New York, New York 10065, United States
  • Rochester, New York 14642, United States
  • Concord, North Carolina 28025, United States
  • Columbus, Ohio 43219, United States
  • Houston, Texas 77030, United States
  • Seattle, Washington 98109, United States
  • Buenos Aires, 1406, Argentina
  • Buenos Aires, C1221ADC, Argentina
  • Buenos Aires, C1431FWO, Argentina
  • Innsbruck, 6020, Austria
  • Salzburg, 5020, Austria
  • Wien, 1090, Austria
  • Bruxelles, 1200, Belgium
  • Gent, 9000, Belgium
  • Mont-godinne, 5530, Belgium
  • Goiania, GO 74140-050, Brazil
  • Porto Alegre, RS 90035-903, Brazil
  • Piracicaba, SP 13419-155, Brazil
  • Sao Paulo, SP 01323-020, Brazil
  • Sao Paulo, SP 04029-000, Brazil
  • Calgary, Alberta T2N 4N2, Canada
  • Vancouver, British Columbia V5Z 4E6, Canada
  • Kingston, Ontario K7L 5P9, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Toronto, Ontario M5G 2M9, Canada
  • Montreal, Quebec H3A 1A1, Canada
  • Montreal, Quebec H3T 1E2, Canada
  • Rijeka, 51000, Croatia
  • Zagreb, 10000, Croatia
  • København, 2100, Denmark
  • Vejle, 7100, Denmark
  • Århus, 8000, Denmark
  • Athens, 115 27, Greece
  • Thessaloniki, 570 10, Greece
  • Bologna, 40138, Italy
  • Brescia, 25123, Italy
  • Milano, 20141, Italy
  • Milano, 20162, Italy
  • Novara, 28100, Italy
  • Pisa, 56100, Italy
  • Reggio Calabria, 89100, Italy
  • Rozzano, 20089, Italy
  • Amsterdam, 1105 AZ, Netherlands
  • Groningen, 9713 GZ, Netherlands
  • Rotterdam, 3015 CE, Netherlands
  • Rotterdam, 3075EA, Netherlands
  • Warszawa, 02-097, Poland
  • Warszawa, 02-781, Poland
  • Palma de Mallorca, Islas Baleares 07198, Spain
  • La Coruna, La Coruña 15006, Spain
  • Barcelona, 08025, Spain
  • Barcelona, 08035, Spain
  • Madrid, 28046, Spain
  • Salamanca, 37007, Spain
  • Sevilla, 41013, Spain
  • Valencia, 46010, Spain
  • Zaragoza, 50009, Spain
  • Huddinge, 14186, Sweden
  • Malmo, 205 02, Sweden
  • St. Gallen, 9007, Switzerland
  • Zürich, 8091, Switzerland
  • Istanbul, 34365, Turkey
  • Izmir, 35100, Turkey
  • London, N6A 4L6, United Kingdom
09

References and documents

Publications

  • Gibiansky E, Gibiansky L, Buchheit V, Frey N, Brewster M, Fingerle-Rowson G, Jamois C. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. Br J Clin Pharmacol. 2019 Sep;85(9):1935-1945. doi: 10.1111/bcp.13974. Epub 2019 Jul 12. PubMed 31050355 ↗
  • Kostakoglu L, Goy A, Martinelli G, Caballero D, Crump M, Gaidano G, Baetz T, Buckstein R, Fine G, Fingerle-Rowson G, Berge C, Sahin D, Press O, Sehn L. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. Leuk Lymphoma. 2017 Feb;58(2):372-381. doi: 10.1080/10428194.2016.1196815. Epub 2016 Jun 24. PubMed 27339738 ↗
  • Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol. 2015 Oct 20;33(30):3467-74. doi: 10.1200/JCO.2014.59.2139. Epub 2015 Aug 17. PubMed 26282650 ↗
  • Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G, Frances-Lasserre S, Carlile DJ, Crump M. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2012 May 31;119(22):5118-25. doi: 10.1182/blood-2012-02-408773. Epub 2012 Mar 20. PubMed 22438256 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Sep 2011 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2007
First posted
Dec 19, 2007
Start
Jan 2008
Primary completionActual
Sep 2011
CompletionActual
Mar 2013
Results first posted
Mar 31, 2014
Last update
Aug 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00576758
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 19, 2007
Start date
Jan 2008
Primary completion
Sep 2011
Completion
Mar 2013
Results posted
Mar 31, 2014
Last update
Aug 19, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion